Quizartinib and High-dose Ara-C plus Mitoxantrone in Relapsed/Refractory AML with FLT3-ITD

Abstract excerpt

<title>Abstract</title> <p><bold>Background: </bold>About 50% of older patients with acute myeloid leukemia (AML) fail to attain complete remission (CR) following cytarabine plus anthracycline-based induction therapy. Salvage chemotherapy regimens are based on high dose cytarabine (HiDAC), which is frequently combined with mitoxantrone (HAM regimen). However, CR rates remain low, with less than one-third of the p...

Topics

Open a Topic to create a Post that cites this publication.

• Antineoplastic Agents
• Antineoplastic Combined Chemotherapy Protocols
• Benzothiazoles
• fms-Like Tyrosine Kinase 3
• Leukemia, Myeloid, Acute
• Mutation
• Phenylurea Compounds
• Protein Kinase Inhibitors

Identifiers and source

Literature Corpus work

c62e4be4-e4ac-52fb-9a02-288bc039271c

DOI

10.21203/rs.3.rs-1117424/v1